Oxyntomodulin: actions and role in diabetes

Research output: Contribution to journal › Review › Research › peer-review

Standard

Oxyntomodulin : actions and role in diabetes. / Holst, Jens J.; Albrechtsen, Nicolai J. Wewer; Gabe, Maria Buur Nordskov; Rosenkilde, Mette Marie.

In: Peptides, Vol. 100, 2018, p. 48-53.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Holst, JJ, Albrechtsen, NJW, Gabe, MBN & Rosenkilde, MM 2018, 'Oxyntomodulin: actions and role in diabetes', Peptides, vol. 100, pp. 48-53. https://doi.org/10.1016/j.peptides.2017.09.018

APA

Holst, J. J., Albrechtsen, N. J. W., Gabe, M. B. N., & Rosenkilde, M. M. (2018). Oxyntomodulin: actions and role in diabetes. Peptides, 100, 48-53. https://doi.org/10.1016/j.peptides.2017.09.018

Vancouver

Holst JJ, Albrechtsen NJW, Gabe MBN, Rosenkilde MM. Oxyntomodulin: actions and role in diabetes. Peptides. 2018;100:48-53. https://doi.org/10.1016/j.peptides.2017.09.018

Author

Holst, Jens J. ; Albrechtsen, Nicolai J. Wewer ; Gabe, Maria Buur Nordskov ; Rosenkilde, Mette Marie. / Oxyntomodulin : actions and role in diabetes. In: Peptides. 2018 ; Vol. 100. pp. 48-53.

Bibtex

@article{d93172b12e7740fcbcda6cb16f68399b,
title = "Oxyntomodulin: actions and role in diabetes",
abstract = "Oxyntomodulin is a product of the glucagon precursor, proglucagon, produced and released from the endocrine L-cells of the gut after enzymatic processing by the precursor prohormone convertase 1/3. It corresponds to the proglucagon sequence 33-69 and thus contains the entire glucagon sequence plus a C-terminal octapeptide, comprising in total 37 amino acids. As might have been expected, it has glucagon-like bioactivity, but also and more surprisingly also activates the receptor for GLP-1. This has given the molecule an interesting status as a glucagon-GLP-1 co-agonist, which is currently attracting considerable interest for its potential in the treatment of diabetes and obesity. Here, we provide an update on oxyntomodulin with a focus on its potential role in metabolic diseases.",
keywords = "Journal Article, Review, Diabetes, Oxyntomodulin, Proglucagon",
author = "Holst, {Jens J.} and Albrechtsen, {Nicolai J. Wewer} and Gabe, {Maria Buur Nordskov} and Rosenkilde, {Mette Marie}",
note = "Copyright {\textcopyright} 2017 Elsevier Inc. All rights reserved.",
year = "2018",
doi = "10.1016/j.peptides.2017.09.018",
language = "English",
volume = "100",
pages = "48--53",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Oxyntomodulin

T2 - actions and role in diabetes

AU - Holst, Jens J.

AU - Albrechtsen, Nicolai J. Wewer

AU - Gabe, Maria Buur Nordskov

AU - Rosenkilde, Mette Marie

N1 - Copyright © 2017 Elsevier Inc. All rights reserved.

PY - 2018

Y1 - 2018

N2 - Oxyntomodulin is a product of the glucagon precursor, proglucagon, produced and released from the endocrine L-cells of the gut after enzymatic processing by the precursor prohormone convertase 1/3. It corresponds to the proglucagon sequence 33-69 and thus contains the entire glucagon sequence plus a C-terminal octapeptide, comprising in total 37 amino acids. As might have been expected, it has glucagon-like bioactivity, but also and more surprisingly also activates the receptor for GLP-1. This has given the molecule an interesting status as a glucagon-GLP-1 co-agonist, which is currently attracting considerable interest for its potential in the treatment of diabetes and obesity. Here, we provide an update on oxyntomodulin with a focus on its potential role in metabolic diseases.

AB - Oxyntomodulin is a product of the glucagon precursor, proglucagon, produced and released from the endocrine L-cells of the gut after enzymatic processing by the precursor prohormone convertase 1/3. It corresponds to the proglucagon sequence 33-69 and thus contains the entire glucagon sequence plus a C-terminal octapeptide, comprising in total 37 amino acids. As might have been expected, it has glucagon-like bioactivity, but also and more surprisingly also activates the receptor for GLP-1. This has given the molecule an interesting status as a glucagon-GLP-1 co-agonist, which is currently attracting considerable interest for its potential in the treatment of diabetes and obesity. Here, we provide an update on oxyntomodulin with a focus on its potential role in metabolic diseases.

KW - Journal Article

KW - Review

KW - Diabetes

KW - Oxyntomodulin

KW - Proglucagon

U2 - 10.1016/j.peptides.2017.09.018

DO - 10.1016/j.peptides.2017.09.018

M3 - Review

C2 - 29412831

VL - 100

SP - 48

EP - 53

JO - Peptides

JF - Peptides

SN - 0196-9781

ER -

ID: 189765037